The Manufacturers Life Insurance Company purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,007 shares of the company’s stock, valued at approximately $864,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Navalign LLC acquired a new stake in Mineralys Therapeutics in the 4th quarter worth about $33,000. KBC Group NV acquired a new position in shares of Mineralys Therapeutics during the first quarter valued at approximately $33,000. Royal Bank of Canada lifted its position in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after acquiring an additional 1,107 shares in the last quarter. FNY Investment Advisers LLC lifted its position in shares of Mineralys Therapeutics by 400.0% in the second quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock valued at $67,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after acquiring an additional 1,993 shares during the last quarter. 84.46% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Mineralys Therapeutics news, Director Daphne Karydas sold 3,000 shares of the firm’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the sale, the director directly owned 6,200 shares of the company’s stock, valued at $155,000. This trade represents a 32.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.90, for a total value of $2,696,811.60. Following the completion of the sale, the insider directly owned 38,400 shares of the company’s stock, valued at $994,560. This trade represents a 73.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 224,333 shares of company stock worth $5,806,213. 18.94% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Get Our Latest Stock Report on Mineralys Therapeutics
Mineralys Therapeutics Trading Down 0.2%
MLYS opened at $28.21 on Friday. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -6.65 and a beta of 0.68. The company’s 50 day simple moving average is $27.02 and its two-hundred day simple moving average is $27.09. Mineralys Therapeutics, Inc. has a 1-year low of $22.30 and a 1-year high of $47.65. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). Analysts expect that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.
Mineralys Therapeutics Company Profile
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Featured Stories
- Five stocks we like better than Mineralys Therapeutics
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Want to see what other hedge funds are holding MLYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report).
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
